Effect of calcium antagonists on hypertension and diabetes in new hypertensive diabetic models.
Hypertension in diabetic patients is more common than in controls, contributes substantially to their increased cardiovascular morbidity and mortality, and should be treated as accurately as diabetes mellitus itself. The purpose of this study was to investigate the effect of calcium antagonists on hypertension and diabetes in hypertensive diabetic rats, which were newly established by neonatal injection of streptozotocin in spontaneously hypertensive rats. At the age of 6 months, hypertensive diabetic rats and control hypertensive nondiabetic rats were treated with hydralazine, diltiazem, or nifedipine for 2 months. In diabetics, antihypertensive therapy not only prevented the progression of nephropathy but also improved glucose metabolism by increasing insulin secretion. Calcium antagonists in this study reduced urinary protein excretion, and nifedipine relieved hypoalbuminemia. Hydralazine had no beneficial effect on urinary protein excretion. Calcium antagonists as compared to hydralazine decreased the heart weight. Calcium antagonists have a beneficial effect on cardiac hypertrophy. Good correlations have been found between kidney weight and blood pressure in hypertensive diabetic rats. It is suggested that blood pressure reflects increase in kidney weight in diabetic patients.